Wuhan Mingde Biotechnology Co., Ltd. (002932.SZ) was established in 2008 and is located in Wuhan Optical Valley Bio-City, a national biological industry base. It is a company focused on the independent research and development, production and sales of in vitro diagnostic products, providing five major centers. The national high-tech enterprise of medical informationization overall solutions and third-party medical testing services.

After years of technological accumulation, a rich product matrix supported by 10 major technology platforms has been built, covering the product lines of immune, blood gas, and molecular diagnosis, forming an area with immediate and accurate diagnosis products as the cornerstone and emergency and critical illness information system as the bridge. An overall solution for collaborative treatment-based smart diagnosis can realize the full process layout of pre-hospital, intermediate and post-hospital. Currently, the business has covered 7,500 medical institutions in 30 provinces, municipalities and autonomous regions across the country, providing product services and technical support to more than 50 countries and regions around the world.

Mingde Biology focuses on the treatment of critical and critical care, in line with the new requirements of national emergency emergency services, and provides medical institutions with an overall solution of "emergency and critical care information management platform + inspection and inspection equipment + center certification consultation + normalized operation" to achieve "prevention, The full process management of rescue, treatment and health will help the intelligent transformation and upgrading of the five major centers in the country and the construction of special disease prevention and control system. After years of deep cultivation and adhering to the customer-centric service concept, Mingde has not only won the recognition of customers, but also gained high recognition from the industry .

Mingde Bio attaches great importance to technical accumulation and product R&D innovation, has an independent R&D center and a high-tech R&D team. It currently has more than 1,200 employees and an elite R&D team with a return doctoral degree as the core. Degrees account for more than 30%, and R&D investment in 2022 exceeds 388 million. Up to now, Mingde Biologics has obtained more than 200 registration certificates for Class II and III medical device, and has more than 100 independent intellectual property rights, including core invention patents, software works, etc. More than 100 products have passed the EU CE certification and NMPA certification. After years of deep cultivation, Mingde Biotech has developed into a cutting-edge supplier of comprehensive in vitro diagnostic solutions in China. It has successively won the honors of "National Specialized and New Small Giant Enterprise Award", "National Enterprise Technology Center", "National Science and Technology System Fighting the New Coronavirus Epidemic-Advanced Collective", and "Top 100 Chinese Pharmaceutical Influential Enterprises".

Mingde Biology will continue to provide high-quality products and services for human health, create a closed service loop centered on human medical and health needs, and always practice the mission of allowing everyone to enjoy health.